Potassium channels as therapeutic targets for autoimmune disorders

Heike Wulff, Christine Beeton, K. George Chandy

Research output: Contribution to journalArticlepeer-review

120 Scopus citations


In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Issue number5
StatePublished - Sep 2003


  • Effector memory T-cells
  • IKCa1
  • Immunosuppression
  • Kv1.3
  • Multiple sclerosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Potassium channels as therapeutic targets for autoimmune disorders'. Together they form a unique fingerprint.

Cite this